Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1991 Apr;46(4):239–241. doi: 10.1136/thx.46.4.239

Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.

A M Dalzell 1, D Sunderland 1, C A Hart 1, D P Heaf 1
PMCID: PMC463083  PMID: 1903896

Abstract

Ceftazidime was used as the only intravenous agent for treating lower respiratory tract infections in patients with cystic fibrosis. The risks of inducing beta lactamases and conferring antibiotic resistance are high when monotherapy is used; so the emergence of resistant bacteria was studied prospectively in the sputum of 120 patients. The mean age of patients was 9.0 (range 0.3-25) years and there were equal number of male and female patients. Pseudomonas aeruginosa was the only ceftazidime resistant bacterium to be isolated from the respiratory tract, and was identified only in chronically colonised patients. Ceftazidime resistance occurred in 103 (14%) of 750 P aeruginosa isolates, and in 16 of 36 chronically colonised patients. Ceftazidime resistant organisms were isolated from the faeces of 17 of 64 patients investigated. Eighty two per cent of the resistant faecal organisms were single isolates: the same resistant organism in faeces was isolated from successive samples in only two patients. In no case was the ceftazidime resistant enteric isolate the same as that from sputum. Patients chronically colonised by P aeruginosa did not harbour ceftazidime resistant enteric organisms any more than non-colonised patients. The use of ceftazidime as a single intravenous agent in treating chest exacerbations in cystic fibrosis does not induce a reservoir of ceftazidime resistant bacteria.

Full text

PDF
239

Images in this article

240Image
on p.240

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dodge J., Zamiri I., Goodchild M., Ingram P. Experience with ceftazidime in cystic fibrosis. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):325–329. doi: 10.1093/jac/12.suppl_a.325. [DOI] [PubMed] [Google Scholar]
  2. Friend P. A. Pulmonary infection in cystic fibrosis. J Infect. 1986 Jul;13(1):55–72. doi: 10.1016/s0163-4453(86)92325-x. [DOI] [PubMed] [Google Scholar]
  3. Hettiaratchy I. G., Cooke E. M., Shooter R. A. Colicine production as an epidemiological marker of Escherichia coli. J Med Microbiol. 1973 Feb;6(1):1–11. doi: 10.1099/00222615-6-1-1. [DOI] [PubMed] [Google Scholar]
  4. Nicas T. I., Hancock R. E. Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant. J Bacteriol. 1983 Jan;153(1):281–285. doi: 10.1128/jb.153.1.281-285.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Padoan R., Cambisano W., Costantini D., Crossignani R. M., Danza M. L., Trezzi G., Giunta A. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatr Infect Dis J. 1987 Jul;6(7):648–653. doi: 10.1097/00006454-198707000-00006. [DOI] [PubMed] [Google Scholar]
  6. Sanders C. C. Novel resistance selected by the new expanded-spectrum cephalosporins: a concern. J Infect Dis. 1983 Mar;147(3):585–589. doi: 10.1093/infdis/147.3.585. [DOI] [PubMed] [Google Scholar]
  7. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  8. Thomassen M. J., Klinger J. D., Badger S. J., van Heeckeren D. W., Stern R. C. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr. 1984 Mar;104(3):352–356. doi: 10.1016/s0022-3476(84)81094-x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES